Indegene Ltd

Director resignation

• Resignation of Mr. Mark F. Dzialga as Non-Executive Non-Independent Director, effective 29 Oct 2026, due to stake sale.
• He ceases as a Member of Nomination & Remuneration and Investment Committees from 29 Oct 2026.

Indegene Limited: Trading window closed from October 1, 2026 for quarter and half-year ended September 30, 2026; reopens 48 hours after results are declared and disseminated

Event overview

• Indegene Digital Summit 2026 held Sept 22 in Philadelphia with 200+ leaders.

Strategic focus

• Discussed translating AI investments into enterprise outcomes and AI-native operating models.

Awards and recognition

• VITAL Awards recognized leaders in Organizational, Market, and Transformational categories.

Management commentary

• Quote from Manish Gupta highlighted AI-enabled enterprise transformation.

Merger details

• Merger between Indegene Healthcare Germany GmbH and Trilogy Writing & Consulting GmbH registered Sept 9, 2026.
• Surviving entity renamed to Indegene Healthcare Germany GmbH, effective Sept 9, 2026.
• Internal restructuring of indirect German subsidiaries; no impact on business operations, shareholding, or finances.
• Projected revenue for Indegene Healthcare Germany GmbH for FY 2026-27: €20,100,000.
• Name change registered with Commercial Register on Sept 9, 2026.
• Transaction is non-cash and involves no share exchange.
• Annexure I confirms transferor and transferee identities and scope.

Litigation Update

• U.S. District Court preliminarily approved the proposed class action settlement.
• Notice process approved; settlement administrator appointed; final approval hearing set for 12 January 2027.
• Preliminary approval does not finalise the settlement; completion depends on notice and claims process.
• Maximum settlement fund is USD 4.72 million; payments USD 250 per valid claim.
• Payments depend on valid claims; no payments yet; subject to court approval.

Meeting Details

• Dates: 24–25 August 2026; times not specified.
• 24 Aug 2026: Online 1x1 with MFS International Singapore.
• 24 Aug 2026: Online 1x1 with ASK Investment Managers.
• 24 Aug 2026: Online 1x1 with Mirae Mutual Fund.
• 25 Aug 2026: In-person 1x1 with Goldman Sachs Asset Management, Bengaluru.
• 25 Aug 2026: Online 1x1 with Seven Canyon Advisors.

Participants

• Company officials will participate in meetings.
• Company Secretary and Compliance Officer to represent Indegene.

Purpose

• Intimation of Schedule of Investor / Analyst meetings.

Additional Notes

• No unpublished price sensitive information will be shared.
• Information will be available on the company website.

Litigation status

• Definitive settlement terms substantially concluded; execution authorized after clarifications on August 18, 2026.
• Settlement with Progressive Health and Rehab Corp. in the U.S. District Court, New Jersey.

Settlement framework

• Maximum settlement fund USD 4.72 million; USD 250 per eligible claim.
• Settlement is claims-made; actual payouts depend on valid/approved claims; no upfront funding required.

Administration and timing

• Notice via fax or first-class mail; administration cost about USD 42,559.
• Next steps: execution, court filing, preliminary approval, class notice, and final court approval.

Impact and governance

• Settlement does not admit liability; accounting impact to be determined under applicable standards.

AGM Details

• AGM held on August 13, 2026 at 4:30 PM IST via VC/OAVM.
• Quorum achieved via video conference; remote e-voting available; no record date stated.

Resolutions & Outcomes

• Item 1: Adoption of standalone and consolidated financial statements — Passed.
• Item 2: Declaration of final dividend — Passed; INR 2.25 per share proposed.
• Item 3: Appointment of Manish Gupta as director liable to retire by rotation — Passed.
• Item 4: Appointment of Dr. Sanjay Suresh Parikh as director liable to retire by rotation — Passed.
• Item 5: Appointment of Jill Mary DeSimone as Independent Director — Passed.

Dividends & Capital Allocation

• Final dividend of INR 2.25 per share was recommended by the board.
• Strong cash flow supports continued dividend sustainability and capital discipline.

Acquisitions & Strategic Outlook

• BioPharm acquisition completed; total cost around INR 887 crores; USD 104 million.
• USD 65 million paid at closing; USD 19 million earn-out due 2027.
• Two European acquisitions completed and integrated.
• FY26 revenue exceeded INR 3,500 crores; quarterly revenue over INR 1,000 crores.
• Board to pursue further AI-led investments and selective acquisitions if returns justify.

Auditors & Governance

• Statutory auditor Deloitte Haskins & Sells issued unqualified opinions on financials.
• Secretarial auditor qualifications noted; management responses published in annual report.

Director appointment

• Ms Jill Mary De Simone appointed Independent Director for a 3-year term from 22-01-2026 to 21-01-2029.
• Profile: Biopharma executive; former Merck US Oncology President; governance and board experience.
• Relationships: Not related to any other Director.
• Not debarred by SEBI or other authorities.